Topic Duchenne muscular dystrophy

News Duchenne muscular dystrophy

• Big Pharma and Biotech Increasingly Tackling Rare and Niche Diseases

  Rare and niche diseases are being increasingly spotlighted by pharmaceutical and biotechnology corporations in the hope of developing initial treatments or improving upon existing therapies for these conditions, according to a new report released by GlobalData.The new report, "Rare and Niche Disease more

• Prosensa Therapeutics awarded top prize for biotechnology innovation in Europe winning EuropaBio's 2011 Most Innovative Biotech SME Award

  At the EuropaBio event entitled "Biotechnology: what's in it for you", hosted at the European Parliament by Julie Girling, MEP, Prosensa Therapeutics was revealed as this year's winner of EuropaBio’s Most Innovative European Biotech SME Award.The winning SME fought off stiff competition from 26 othe more

• Prosensa Advances Three Exon Skipping Candidates for Duchenne Muscular Dystrophy into the Next Development Stage

  Prosensa announced that they have agreed with GlaxoSmithKline (GSK) to advance three further exon skipping compounds (PRO044, PRO045 and PRO053) into the next development stage under their ongoing collaboration relationship in Duchenne Muscular Dystrophy (DMD).The two companies have agreed upon the more

Publications Duchenne muscular dystrophy

• Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping

  Duchenne muscular dystrophy (DMD) is a severe neuromuscular disorder caused by mutations in the dystrophin gene that result in the absence of functional protein. Antisense-mediated exon skipping is one of the most promising approaches for the treatment of DMD and recent clinical trials have demonst more

• Upregulation of brain utrophin does not rescue behavioral alterations in dystrophin-deficient mice

  Dystrophin, the protein responsible for X-linked Duchenne muscular dystrophy (DMD), is normally expressed in both muscle and brain, which explains that its loss also leads to cognitive deficits. The utrophin protein, an autosomal homolog, is a natural candidate for dystrophin replacement in patient more

• Amelioration of Duchenne muscular dystrophy in mdx mice by elimination of matrix-associated fibrin-driven inflammation coupled to the {alpha}M{beta}2 leukocyte integrin receptor

  In Duchenne muscular dystrophy (DMD), a persistently altered and reorganizing extracellular matrix (ECM) within inflamed muscle promotes damage and dysfunction. However, the molecular determinants of the ECM that mediate inflammatory changes and faulty tissue reorganization remain poorly defined. H more

Market studies Duchenne muscular dystrophy

• Duchenne Muscular Dystrophy – Pipeline Review, H1 2012

  Introduction Global Markets Direct’s, 'Duchenne Muscular Dystrophy - Pipeline Review, H1 2012', provides an overview of the Duchenne Muscular Dystrophy therapeutic pipeline. This report provides information on the therapeutic development for Duchenne Muscular Dystrophy, complete with latest update more

• CepTor Corporation - Strategic SWOT Analysis Review

  CepTor Corporation (CepTor) is a development-stage biopharmaceutical company that is engaged in the discovery, development and commercialization of proprietary, cell-targeted therapeutic products for the treatment of neurodegenerative and neuromuscular diseases with a special focus on orphan disease more

• Duchenne Muscular Dystrophy - Pipeline Review, Q1 2011

  Introduction Global Markets Direct’s, 'Duchenne Muscular Dystrophy - Pipeline Review, Q1 2011', provides an overview of the Duchenne Muscular Dystrophy therapeutic pipeline. This report provides information on the therapeutic development for Duchenne Muscular Dystrophy, complete with latest updates more

Websites Duchenne muscular dystrophy